NCT03685630View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

March 27, 2021

Study Completion Date

March 27, 2021

Conditions
Partial Seizures With or Without Secondary GeneralizationEpilepsy
Interventions
DRUG

Brivaracetam

"* Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection"

Trial Locations (9)

Unknown

Ep0118 116, Asaka

Ep0118 126, Bunkyō City

Ep0118 111, Hamamatsu

Ep0118 121, Itami

Ep0118 142, Kamakura

Ep0118 112, Kōshi

Ep0118 104, Shizuoka

Ep0118 138, Tsukuba

Ep0118 109, Yamagata

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03685630 - A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization | Biotech Hunter | Biotech Hunter